Abstract

Background: Bedaquiline, a potent antitubercular drug used in the treatment of multidrug-resistant strains, suffers from low oral bioavailability, a slow onset of therapeutic action, and side effects. This investigation proposes the development of nanocarriers for the drug to improve drug release and estimate its effect on oral absorption through an in-silico model. Initially, a custom design was investigated to estimate the effects of composition and process on the entrapment and particle size of the carriers. The nanocarriers were subjected to studies on surface characteristics, surface morphology, thermal properties, drug release, ex vivo permeation, and antimicrobial efficacy. In silico predictions of bioavailability and pharmacokinetic parameters of the optimized formulation were conducted using GastroPlus® software.

By Nandhini Rajendhiran & Sayani Bhattacharyya